News Archive: February 2026

All peptide regulatory news from February 2026.

22 Articles in February 2026

Federal Regulations February 25, 2026

FDA Peptide Naming and Labeling Requirements: How Mislabeling Leads to Enforcement

FDA peptide labeling requirements are strict and frequently enforced. Learn how mislabeled peptide products trigger warning letters, seizures, and injunctions.

State Laws February 25, 2026

Georgia Peptide Therapy Laws: What Clinics and Patients Need to Know in 2026

A breakdown of Georgia's peptide therapy laws in 2026, covering state pharmacy board rules, compounding regulations, and telehealth prescribing requirements.

State Laws February 18, 2026

Ohio Peptide Compounding Regulations and Recent Pharmacy Board Decisions

Ohio's State Board of Pharmacy has issued new guidance on peptide compounding, affecting how pharmacies can prepare and dispense peptide therapies under state law.

State Laws February 18, 2026

Colorado State Laws on Peptide Therapy Clinics and Medical Practice

Colorado's medical board and pharmacy regulations create specific requirements for peptide therapy clinics, addressing telemedicine, prescribing standards, and pharmacy operations.

Federal Regulations February 18, 2026

FDA's Evolving Stance on GHK-Cu and Cosmetic Peptide Ingredients

The FDA's regulatory approach to cosmetic peptides like GHK-Cu demonstrates the blurry line between cosmetics and drugs, with enforcement implications for the growing peptide skincare industry.

State Laws February 18, 2026

Are Peptides Legal in Michigan? 2026 Laws and Regulations

Michigan residents seeking peptide therapy face a complex legal landscape. This guide explains current Michigan peptide laws, prescription requirements, and what's legal for consumers in 2026.

Legal Analysis February 18, 2026

Will Compounded Semaglutide Become Illegal? Patent Law Explained

With Novo Nordisk's semaglutide patents extending into the 2030s, consumers wonder if compounded versions will be banned. We explain how patent law, FDA shortage rules, and pharmacy regulations determine compounded semaglutide's legal future.

Legal Analysis February 18, 2026

Can Peptide Companies Legally Make Health Claims? FDA and FTC Rules

Peptide sellers frequently make bold health claims, but most violate FDA and FTC regulations. Learn what companies can legally claim about peptides and how illegal marketing puts consumers at risk.

Federal Regulations February 18, 2026

Are Peptide Supplements FDA Approved? What Consumers Need to Know

Most peptide supplements on the market are not FDA approved, and many are illegally marketed. Learn which peptides have FDA approval, how to identify legal products, and what "FDA approved" really means.

Enforcement Actions February 18, 2026

How to Spot Fake Peptides: Legal Risks of Counterfeit Products

Counterfeit and mislabeled peptides flood the market, posing serious health and legal risks. Learn how to identify fake peptides, understand testing methods, and know your legal rights when dealing with fraudulent products.

Legal Analysis February 18, 2026

Peptide Therapy Side Effects: Your Legal Rights If Something Goes Wrong

When peptide therapy causes harm, patients often don't know their legal options. Learn about liability for peptide therapy injuries, when you can sue, and how to protect your rights if you experience adverse reactions.

Industry News February 18, 2026

Medicare and Insurance Coverage for Peptide Therapy in 2026

Does insurance cover peptide therapy? Medicare and private insurance coverage for peptides depends on FDA approval status, medical necessity, and specific plan policies. This comprehensive guide explains when peptides are covered and how to maximize reimbursement.

Federal Regulations February 11, 2026

FDA Peptide Regulations 2026: What You Need to Know

Comprehensive overview of FDA peptide regulations in 2026, including bulk drug substance categories, compounding restrictions, and how recent actions affect peptide access.

Federal Regulations February 11, 2026

Telehealth Peptide Prescribing Laws: State and Federal Guide

Navigate the legal framework for telehealth peptide prescribing, including federal regulations, state-by-state requirements, and provider and patient considerations.

Federal Regulations February 11, 2026

Compounding Pharmacy Regulations: 503A vs 503B Explained

Understand the critical differences between 503A and 503B compounding pharmacies, how they affect peptide access, quality assurance, and regulatory compliance.

Federal Regulations February 5, 2026

FDA Ruling: Peptides BPC-157 & TB-500 Impacted

FDA Category 2 Peptides: An Analysis of the 2023 Ruling and Its Impact on BPC-157, TB-500, and the Peptide Industry In 2023, the Food and Drug Administration (FDA) implemented a ruling with significant ramifications for the peptide industry, particularly impacting the availability and sourcing o...

Federal Regulations February 5, 2026

DEA Scheduling of Peptides: Which Peptides Are Controlled Substances?

FDA Regulation and Peptide Scheduling: A Deep Dive into DEA Control Overview of the Regulatory Action The Drug Enforcement Administration (DEA) plays a crucial role in regulating peptides in the United States, primarily through its scheduling authority under the Controlled Substances Act (CSA).

Enforcement Actions February 4, 2026

UK Peptide Laws: New MHRA Rules & Import Guide

UK Peptide Laws: MHRA Regulations and Import Rules 2024 - An In-Depth Analysis Overview of the Regulatory Action The United Kingdom's regulatory landscape for peptides is governed primarily by the Medicines and Healthcare products Regulatory Agency (MHRA).

Enforcement Actions February 4, 2026

Canada Peptide Laws: Regulations & Risks

Overview of Health Canada's Peptide Regulations Health Canada's regulation of peptides involves a complex interplay of drug scheduling, prescription requirements, importation rules, and provincial variations.

Industry News February 4, 2026

EU Peptide Regulations: Country Guide

Overview of the Regulatory Action The European Union presents a complex regulatory landscape for peptides, differing significantly from the more unified approach observed in the United States under the FDA.

Federal Regulations February 3, 2026

Semaglutide: Prescription Laws by Country

Semaglutide Legal Status: A Global Analysis of Prescription Requirements and Regulatory Implications Overview of the Regulatory Action Semaglutide, marketed under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management), has experienced a surge in global demand.

Federal Regulations February 3, 2026

Mounjaro Legal? 2024 Prescription Guide

Here is the requested analysis: Tirzepatide (Mounjaro) Legal Status and Prescription Requirements in 2024: A Regulatory Analysis Tirzepatide, marketed as Mounjaro, has rapidly gained prominence in both diabetes management and, increasingly, weight loss.